{"id":"W2557375195","doi":"10.1182/blood.v126.23.344.344","title":"Dose-Optimized Nilotinib (NIL) in Patients (Pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Results from ENESTxtnd Study","year":2015,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Nilotinib; Medicine; Internal medicine; Adverse effect; Clinical endpoint; Imatinib mesylate; Imatinib; Phases of clinical research; Gastroenterology; Myeloid leukemia; Clinical trial; Surgery","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002261397,0.0005337762,0.0009704983,0.0001646768,0.0001538163,0.0006379207,0.0004995198,0.0003809055,0.0008854256],"category_scores_gemma":[0.0009101584,0.0001783089,0.0007789083,0.0002357914,0.0002545913,0.000448722,0.0003631412,0.0009396708,0.0002236508],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007482204,"about_ca_system_score_gemma":0.0007248438,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005402739,"about_ca_topic_score_gemma":0.002088754,"domain_scores_codex":[0.9995273,0.0002585228,0.0000334627,0.00006479568,0.0000721699,0.000043615],"domain_scores_gemma":[0.9995198,0.00009920421,0.0001382844,0.00004770486,0.00004877089,0.0001462267],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5626687,0.02763639,0.06238952,0.001412323,0.004058986,0.000599844,0.0003031047,0.01647588,0.05812788,0.0004846918,0.008672992,0.2571697],"study_design_scores_gemma":[0.2616972,0.4864633,0.2000678,0.000180556,0.003338545,0.001504384,0.0001341829,0.006821144,0.01443459,0.0006228826,0.02462608,0.0001092889],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934611,0.003305114,0.0004359364,0.0001809721,0.0000249218,0.0003771672,0.001058894,0.0000284456,0.001127473],"genre_scores_gemma":[0.9885942,0.001951349,0.001960341,0.0004638387,0.00004806049,0.0004045147,0.005300808,0.00002442754,0.001252421],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002261397,"threshold_uncertainty_score":0.01195955,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03109947596682438,"score_gpt":0.2858032722696108,"score_spread":0.2547037963027864,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}